533 related articles for article (PubMed ID: 22122457)
1. Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists on glycemic control, lipid profile and cardiovascular risk.
Derosa G; Maffioli P
Curr Mol Pharmacol; 2012 Jun; 5(2):272-81. PubMed ID: 22122457
[TBL] [Abstract][Full Text] [Related]
2. PPAR-gamma agonists and their role in type 2 diabetes mellitus management.
Bermúdez V; Finol F; Parra N; Parra M; Pérez A; Peñaranda L; Vílchez D; Rojas J; Arráiz N; Velasco M
Am J Ther; 2010; 17(3):274-83. PubMed ID: 20216208
[TBL] [Abstract][Full Text] [Related]
3. Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.
Bajaj M; Suraamornkul S; Hardies LJ; Glass L; Musi N; DeFronzo RA
Diabetologia; 2007 Aug; 50(8):1723-31. PubMed ID: 17520238
[TBL] [Abstract][Full Text] [Related]
4. Combination peroxisome proliferator-activated receptor gamma and alpha agonist treatment in Type 2 diabetes prevents the beneficial pioglitazone effect on liver fat content.
Balasubramanian R; Gerrard J; Dalla Man C; Firbank MJ; Lane A; English PT; Cobelli C; Taylor R
Diabet Med; 2010 Feb; 27(2):150-6. PubMed ID: 20546257
[TBL] [Abstract][Full Text] [Related]
5. Different effects of thiazolidinediones on cardiovascular risk in patients with type 2 diabetes mellitus: pioglitazone versus rosiglitazone.
Simó R; Rodriguez A; Caveda E
Curr Drug Saf; 2010 Jul; 5(3):234-44. PubMed ID: 20210732
[TBL] [Abstract][Full Text] [Related]
6. Peroxisome proliferator-activated receptor-gamma agonists for management and prevention of vascular disease in patients with and without diabetes mellitus.
Ríos-Vázquez R; Marzoa-Rivas R; Gil-Ortega I; Kaski JC
Am J Cardiovasc Drugs; 2006; 6(4):231-42. PubMed ID: 16913824
[TBL] [Abstract][Full Text] [Related]
7. PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.
Wilding JP
Diabetes Obes Metab; 2012 Nov; 14(11):973-82. PubMed ID: 22443197
[TBL] [Abstract][Full Text] [Related]
8. Thiazolidinediones: a review of their mechanisms of insulin sensitization, therapeutic potential, clinical efficacy, and tolerability.
Vasudevan AR; Balasubramanyam A
Diabetes Technol Ther; 2004 Dec; 6(6):850-63. PubMed ID: 15684639
[TBL] [Abstract][Full Text] [Related]
9. Metabolic and additional vascular effects of thiazolidinediones.
Martens FM; Visseren FL; Lemay J; de Koning EJ; Rabelink TJ
Drugs; 2002; 62(10):1463-80. PubMed ID: 12093315
[TBL] [Abstract][Full Text] [Related]
10. Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus.
Defronzo RA; Mehta RJ; Schnure JJ
Hosp Pract (1995); 2013 Apr; 41(2):132-47. PubMed ID: 23680744
[TBL] [Abstract][Full Text] [Related]
11. Thiazolidinediones: effects on insulin resistance and the cardiovascular system.
Quinn CE; Hamilton PK; Lockhart CJ; McVeigh GE
Br J Pharmacol; 2008 Feb; 153(4):636-45. PubMed ID: 17906687
[TBL] [Abstract][Full Text] [Related]
12. Pioglitazone: update on an oral antidiabetic drug with antiatherosclerotic effects.
Pfützner A; Weber MM; Forst T
Expert Opin Pharmacother; 2007 Aug; 8(12):1985-98. PubMed ID: 17696799
[TBL] [Abstract][Full Text] [Related]
13. Improved skeletal muscle oxidative enzyme activity and restoration of PGC-1 alpha and PPAR beta/delta gene expression upon rosiglitazone treatment in obese patients with type 2 diabetes mellitus.
Mensink M; Hesselink MK; Russell AP; Schaart G; Sels JP; Schrauwen P
Int J Obes (Lond); 2007 Aug; 31(8):1302-10. PubMed ID: 17310221
[TBL] [Abstract][Full Text] [Related]
14. Treatment of Mitochondrial Diabetes with a Peroxisome Proliferator-activated Receptor (PPAR)-gamma Agonist.
Ninomiya H; Hirata A; Kozawa J; Nakata S; Kimura T; Kitamura T; Yasuda T; Otsuki M; Imagawa A; Kaneto H; Funahashi T; Shimomura I
Intern Med; 2016; 55(9):1143-7. PubMed ID: 27150869
[TBL] [Abstract][Full Text] [Related]
15. Targeting peroxisome proliferator-activated receptor gamma for generation of antidiabetic drug.
Karak M; Bal NC; Bal C; Sharon A
Curr Diabetes Rev; 2013 Jul; 9(4):275-85. PubMed ID: 23746081
[TBL] [Abstract][Full Text] [Related]
16. PPAR- γ agonist in treatment of diabetes: cardiovascular safety considerations.
Abbas A; Blandon J; Rude J; Elfar A; Mukherjee D
Cardiovasc Hematol Agents Med Chem; 2012 Jun; 10(2):124-34. PubMed ID: 22471957
[TBL] [Abstract][Full Text] [Related]
17. Peroxisome proliferator-activated receptor-gamma agonists in atherosclerosis: current evidence and future directions.
Roberts AW; Thomas A; Rees A; Evans M
Curr Opin Lipidol; 2003 Dec; 14(6):567-73. PubMed ID: 14624133
[TBL] [Abstract][Full Text] [Related]
18. The peroxisome proliferator-activated receptor-gamma agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-alpha-dependent manner in vitro and in vivo in mice.
Orasanu G; Ziouzenkova O; Devchand PR; Nehra V; Hamdy O; Horton ES; Plutzky J
J Am Coll Cardiol; 2008 Sep; 52(10):869-81. PubMed ID: 18755353
[TBL] [Abstract][Full Text] [Related]
19. Do thiazolidinediones still have a role in treatment of type 2 diabetes mellitus?
Consoli A; Formoso G
Diabetes Obes Metab; 2013 Nov; 15(11):967-77. PubMed ID: 23522285
[TBL] [Abstract][Full Text] [Related]
20. Improved insulin sensitivity after treatment with PPARγ and PPARα ligands is mediated by genetically modulated transcripts.
Rasouli N; Kern PA; Elbein SC; Sharma NK; Das SK
Pharmacogenet Genomics; 2012 Jul; 22(7):484-97. PubMed ID: 22437669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
